India, March 17 -- image credit- shutterstock

Akrivia Biosciences, a Mumbai-based deeptech startup in oncology precision diagnostics, has closed its pre-seed funding through Compulsory Convertible Debentures (CCDs) from JITO Incubation and Innovation Foundation (JIIF) and Rebalance Angels.

This funding will be utilised for Proof of Concept trials, the formation of an internal R&D team, and scientific publications that support its breakthrough innovations in cancer treatment.

Akrivia Biosciences is revolutionising cancer diagnostics with its next-generation molecular subtyping tests. By leveraging a multi-omics approach, Akrivia is transforming cancer treatment by providing oncologists with precise and comprehensive data to guide person...